Competitive Intelligence and the Distribution of Circulating Tumor Cell Market Share The distribution of Circulating Tumor Cell Market Share is currently a "clash of the titans" between established medical technology firms and nimble biotechnology startups. The market leaders are those who have successfully navigated the arduous path to FDA and CE-IVD clearance, as regulatory approval is the ultimate barrier to entry in the clinical diagnostic space. These dominant players often use their extensive sales teams to bundle CTC platforms with other oncology products, making it difficult for new entrants to break into the hospital market. However, startups are finding success by targeting the "research-use-only" (RUO) market, providing highly specialized tools for academic labs that need to capture rare cell types that the standard clinical machines might miss. This "bottom-up" approach allows them to build clinical evidence and a loyal user base before seeking formal regulatory approval. Ref - https://www.marketresearchfuture.com/reports/circulating-tumor-cell-market-1362